Industry Bulletins | October 31, 2018
Bain Invests $35 Million In New Company Cerevel To Develop Pfizer’s Neuroscience Pipeline
Private equity firm Bain Capital recently invested $350 million into the creation of Cerevel Therapeutics, a company that will work to create drug treatments for Parkinson’s disease, Alzheimer’s disease, epilepsy, schizophrenia, and addiction disorder. Specifically, the funds come from Bain’s private equity and life sciences funds, and may provide Cerevel with additional capital in the future.
The treatment offerings of Cerevel—a company that results from Pfizer’s divestiture from neuroscience—currently consists of three drugs developed by Pfizer, as well as a number of pre-clinical drugs. The formerly mentioned three include a D1 partial agonist . . .